BioAtla, Inc. (NASDAQ:BCAB) Financings
Financings
| Raise | Date |
|---|---|
| Pre-paid advance convertible into common stock Closed: US$7.13M raised · Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: Yorkville Advisors Global (affiliate) (part of an aggregate $7.5 million advance); Anson Advisors Inc. (funds managed by) (part of an aggregate $7.5 million advance) Use of proceeds: Support operations while finalizing a strategic partnership | Nov 21, 2025 |
| Common stock under Standby Equity Purchase Agreement Announced: Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: Yorkville Advisors Global (affiliate) (commitment to buy up to a total of $15 million of common stock if the Company exercises its option) Use of proceeds: Support operations while finalizing a strategic partnership | Nov 21, 2025 |
| Registered direct offering of shares of common stock with accompanying warrants Announced: about US$9.2M · US$0.952 a share · Warrants at US$1.19 for 66 months · Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) Dealers: Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) (lead) Use of proceeds: Research and development including BA3182 and mecbotamab vedotin data readouts, partnering activities, working capital and general corporate purposes | Dec 20, 2024 |